Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

Published:2017-09-11 Issue:1 Volume:167 Page:81-87
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Niikura Naoki,Shimomura Akihiko,Fukatsu Yumi,Sawaki Masataka,Ogiya Rin,Yasojima Hiroyuki,Fujisawa Tomomi,Yamamoto Mitsugu,Tsuneizumi Michiko,Kitani Akira,Watanabe Junichiro,Matsui Akira,Takahashi Yuko,Takashima Seiki,Shien Tadatoshi,Tamura Kenji,Saji Shigehira,Masuda Norikazu,Tokuda Yutaka,Iwata Hhiroji

Funder

Japan Agency for Medical Research and Development

National Cancer Center Research and Development Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4489-9/fulltext.html

Reference16 articles.

1. Iwamoto T, Fukui N, Kinoshita T et al (2015) Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. Breast Cancer 23(1):62–72

2. Cardoso F, Fallowfield L, Costa A et al (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi25–vi30

3. Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099

4. Harano K, Lei X, Gonzalez-Angulo AM et al (2016) Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159:367–374

5. Yardley DA, Tripathy D, Brufsky AM et al (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110:2756–2764

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial;Clinical Breast Cancer;2024-07

2. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression;Scientific Reports;2023-05-31

3. Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer;Breast Care;2022-12-20

4. Investigating Two Modes of Cancer-Associated Antigen Heterogeneity in an Agent-Based Model of Chimeric Antigen Receptor T-Cell Therapy;Cells;2022-10-09

5. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions;Breast Cancer Research and Treatment;2022-09-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3